Latest News for: ap3
Edit
Covenant HR Announces Inclusion in Lockton & ASHHRA AP3 Partner Program as Healthcare Hiring Complexity Accelerates in 2026
PR Newswire 19 Mar 2026
Edit
The Daily Record - Dunn
18 Mar 2026
Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong ...
The Daily Record - Dunn
18 Mar 2026
Edit
Hastings Tribune
18 Mar 2026
Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing
Hastings Tribune
18 Mar 2026
ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 (Topo 1) inhibitors, commonly used payloads in antibody-drug conjugates (ADCs) ... .
Edit
Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors (Acrivon Therapeutics Inc)
Public Technologies 17 Mar 2026
). The text version of this document is not available ... Disclaimer ... (noodl. 130243469) .
Edit
Sweden’s AP3, AP4 see savings from AP1 axing starting from 2027
IPE 16 Jan 2026
Stockholm-based pensions buffer fund duo says reform-mandated transfer of assets from defunct peer complete, bar under 2% private assets to be managed separately for now ....
Edit
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 (Form 8-K) (Acrivon Therapeutics Inc)
Public Technologies 08 Jan 2026
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11.
- 1